Key statistics dashboard for Cardiff Oncology, Inc. (CRDF). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Stock Data
| Price | $1.35 |
| Market Cap | $104M |
| Enterprise Value | $95.3M |
| Beta | 1.42 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -2.26 |
| Price / Book | 3.49 |
| P/S | 205.58 |
| EV/EBITDA | -2.45 |
| EV/Sales | 187.62 |
| EV/FCF | -2.33 |
| P/FCF | -2.55 |
| Earnings Yield | -43.38% |
| FCF Yield | -39.32% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 100.00% |
| EBIT Margin | -7884.06% |
| EBITDA Margin | -7665.16% |
| Operating Margin | -8320.08% |
| Net Margin | -7884.06% |
| Return on Equity | -103.08% |
| Return on Assets | -107.29% |
| Return on Invested Capital | -156.60% |
| Return on Capital Employed | -159.30% |
Financial Health
| Current Ratio | 3.30 |
| Quick Ratio | 3.30 |
| Cash Ratio | 0.85 |
| Debt / Equity | 0.02 |
| Debt / Assets | 1.22% |
| Net Debt / EBITDA | 0.22 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.01 |
| Book Value per share | 0.39 |
| Cash per share | 0.50 |
| FCF per share | -0.60 |
| Tangible Book Value per share | 0.39 |
| Dividend per share | 0.00 |
Related companies: APLT · CRBP · ELTX · FBRX · IPHA · MIST · MOLN
Explore sector: Healthcare · Biotechnology
More sections of CRDF: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks